drugset
drugset / Trial / NCT05348213

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

NCT05348213 ↗

Phase 2 Recruiting 76 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.

Timeline

Start
2022-05-16
Primary completion
2025-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 10 mg/m2 Intravenous
Subject Pomalidomide Other / unclassified 4 mg Oral
Subject Tofacitinib Small molecule 5 mg Oral
Subject Tucidinostat Small molecule 20 mg Oral
Subject Zanubrutinib Small molecule 160 mg Oral
Background Carboplatin Small molecule 5 unknown Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Ifosfamide Small molecule 1500 mg/m2 Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma